Janux Therapeutics, Inc.
JANX
$29.69
$1.003.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -68.99M | -60.54M | -44.05M | -55.59M | -58.29M |
| Total Depreciation and Amortization | 2.06M | 2.08M | 2.07M | 2.03M | 1.96M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.44M | 21.53M | 11.48M | 12.36M | 12.32M |
| Change in Net Operating Assets | 685.00K | -66.00K | -15.98M | -10.30M | -6.55M |
| Cash from Operations | -43.81M | -36.99M | -46.47M | -51.50M | -50.58M |
| Capital Expenditure | -359.00K | -832.00K | -1.28M | -1.76M | -1.85M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -257.66M | -279.99M | -353.67M | -144.43M | -39.34M |
| Cash from Investing | -258.02M | -280.82M | -354.95M | -146.19M | -41.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 713.24M | 327.42M | 382.38M | 380.14M | 59.55M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 713.24M | 327.42M | 382.38M | 380.14M | 59.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 411.40M | 9.60M | -19.04M | 182.45M | -32.22M |